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Abstract
To identify the genes and pathways that underlie cardiovascular and metabolic phenotypes we performed an integrated
analysis of a mouse C57BL/6J x A/J F2 (B6AF2) cross by relating genome-wide gene expression data from adipose, kidney,
and liver tissues to physiological endpoints measured in the population. We have identified a large number of trait QTLs
including loci driving variation in cardiac function on chromosomes 2 and 6 and a hotspot for adiposity, energy metabolism,
and glucose traits on chromosome 8. Integration of adipose gene expression data identified a core set of genes that drive
the chromosome 8 adiposity QTL. This chromosome 8 trans eQTL signature contains genes associated with mitochondrial
function and oxidative phosphorylation and maps to a subnetwork with conserved function in humans that was previously
implicated in human obesity. In addition, human eSNPs corresponding to orthologous genes from the signature show
enrichment for association to type II diabetes in the DIAGRAM cohort, supporting the idea that the chromosome 8 locus
perturbs a molecular network that in humans senses variations in DNA and in turn affects metabolic disease risk. We
functionally validate predictions from this approach by demonstrating metabolic phenotypes in knockout mice for three
genes from the trans eQTL signature, Akr1b8, Emr1, and Rgs2. In addition we show that the transcriptional signatures for
knockout of two of these genes, Akr1b8 and Rgs2, map to the F2 network modules associated with the chromosome 8 trans
eQTL signature and that these modules are in turn very significantly correlated with adiposity in the F2 population. Overall
this study demonstrates how integrating gene expression data with QTL analysis in a network-based framework can aid in
the elucidation of the molecular drivers of disease that can be translated from mice to humans.
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Introduction
Classical genetic approaches to the study of complex pheno-
types have historically been based on relating DNA variation to
trait differences in populations from specific paired matings. These
quantitative trait locus (QTL) mapping techniques have been
successful in identifying regions of the genome that control
phenotypic variation, but have been less productive when it comes
to the identification of causative functional DNA variants or, more
importantly, how these variants act at the molecular level to drive
phenotypes [1]. More recently, a number of groups have shown
how integration of intermediate molecular phenotypes, such as
gene and protein expression levels, can be used to aid the
reconstruction of these pathways and genes [2–6].
Obesity is a significant health burden in the developed world as
a consequence of the associated co-morbidities of diabetes,
cardiovascular disease, and hypertension [7–9]. Historically,
rodents have been used as models of human obesity and
hypertension because the genetic backgrounds and environmental
influences can be controlled and because there is evidence that
homologous genes are involved [10–12]. Multiple studies of
adiposity and hypertension in genetic crosses from rats and mice
have identified a large number of QTL associated with these traits
[13–18].
PLoS ONE | www.plosone.org 1 December 2010 | Volume 5 | Issue 12 | e14319Here we report results from a mouse F2 intercross population in
which metabolic parameters, blood pressure, and echocardiography
traits were measured and integrated with gene expression data from
adipose, kidney, and liver. In addition to identifying a large number
of clinical trait QTL we identified a locus on mouse chromosome 8
that is responsible for driving the expression of a large number of
genes specifically in the adipose. Using an integrated approach,
including network modeling, we predicted that this gene signature is
causally associated with adiposity phenotypes. We present data to
support this conclusion by showing metabolic phenotypes in three
knockout mouse strains corresponding to genes from the signature.
We also show that adipose signatures associated with these
knockouts map to the predicted co-expression modules linked to
adiposity in the F2 population.
Results
Cardiovascular and Metabolic Traits in F2 progeny of a
C57BL/6J x A/J cross
An F2 population was derived from a C57BL/6J x A/J cross
(B6AF2) and traits were measured in 360 male and female progeny
using a phenotyping platform outlined in Figure S1. Mice were
placed on a high-fat high-salt balanced diet at week 7 and
maintained on this chow until termination at week 16. Five
principle phenotyping components were used: blood pressure and
heart rate by tail cuff at week 10; echocardiography at week 10;
energy utilization by Oxymax at week 12; oral glucose tolerance
test (OGTT) at week 13; intra-peritoneal insulin sensitivity test
(IPIST) at week 14; and body composition by Dexascan at week
15. In addition, a number of endpoints relevant to size and
adiposity, and serum for blood analytes including lipids, were
collected at final necropsy. Table S1 shows a list of traits and the
mean +/2SD values in the parental, F1, and F2 populations.
Mapping of QTL for body composition,
echocardiography, blood pressure, and cholesterol traits
A genetic map was derived from the genotype data for the F2
progeny and used to identify trait QTL. Table 1 shows the 51
genome-wide significant trait QTL (LOD$4.3/FDR=0.10) [19]
that were mapped for a total of 27 selected traits. A full set of QTL
for all traits calculated for all animals, as well as males and females
separately, is given in Table S2.
Notable hotspots for QTL associated with body composition,
size, and glucose/insulin traits mapped to chromosomes 1, 6, and
8. These QTL likely correspond to QTL for weight previously
reported by Zhang and Gershenfeld in intercross (F2) and
backcross (N2) populations from these strains [20]. These authors
reported a significant QTL for weight at week 8, Bw8q1 on
chromosome 1, as well as a suggestive QTL on chromosome 8 for
the same trait, and a suggestive QTL for 2-week weight gain on
chromosome 6 [20]. In addition, Shao et al have used
chromosome substitution strains to dissect the chromosome 6
QTL and provide evidence that it is a complex QTL consisting of
four distinct loci [21].
QTL hotspots associated with composition and glucose/insulin
traits on chromosomes 6 and 8 in this study are shown in Figure 1.
Both of these loci have effects on multiple fat depots in the mouse
including gonadal, mesenteric, and subcutaneous adipose. In
addition, % lean mass and tissue weight traits, as a fraction of total
weight of the mouse, also map to these loci. This probably reflects
secondary effects of the increases in fat depots rather than a direct
effect on these traits. This hypothesis is supported by the
observation that absolute measures of either lean mass or tissue
weight fail to show significant or suggestive QTL at these loci. We
conclude that the main effects of the chromosome 6 and
chromosome 8 loci with regard to body composition are on
adiposity. In addition, traits related to maintenance of blood
glucose levels map to both loci while traits relevant to energy
metabolism (Heat, VO2, and VC02) and triglyceride level are
present on chromosome 8 (Figure 1, Figure S2, Table 1, and
Table S2). Overall, these two loci regulate traits that in humans
are associated with metabolic syndrome (obesity, diabetes, and
lipid-related traits). While the adipose traits show very significant
correlation across the population, the lipid and glucose/insulin-
related traits show distinct distributions across individuals
suggestive of complex genetic control (Figure S3). A subsequent
section investigates the genes and networks that are driving this
phenotypic variation (see below).
We detected a number of QTL associated with blood pressure,
heart rate, and echocardiography traits (Figure 2). On chromosome
1 we identified an overlapping QTL for systolic blood pressure and
heart rate (QTL peak =56 cm & 49 cM; maximum LOD=4.8 &
4.5, respectively) (Figure 2A). This probably corresponds to the
Abbp1 locus identified by Woo et al in a similar strain background
[18]. These investigators identified additional QTL: Abbp2 on
chromosome 4 at 25 cm, Abbp3 on chromosome 7 at 25 cM, and
Abbp4 on chromosome 11 at 58 cM. Interestingly, we detected no
signal above LOD=3 for a blood pressure QTL on chromosome
11 but did detect a QTL on chromosome 7 (QTL peak=47 cM;
maximum LOD=4.2) and a QTL on chromosome 4 (QTL
peak=19 cM; maximum LOD=3.0) when we adjusted for serum
insulin levels (Table S2). In regard to electrocardiographic traits, we
identified a cluster on mouse chromosome 2 containing QTL for
velocity time integral, cardiac output, heart rate, LV mass,
LV_EDD, and LV_ESD (Figure 2B). These traits relate to cardiac
structure and function, in particular left ventricular function,
indicating the presence of a locus on chromosome 2 that regulates
overall cardiac output. In this regard, it is interesting to note that
Suzuki et al have mapped a genetic modifier of murine dilated
myopathy (Hrtfm1) to an overlapping region of chromosome 2 in a
C57BL/6J x DBA/2J backcross [22]. In comparison with the
chromosome 2 locus that appears to drive variation in cardiac
output related to left ventricular function, we also identified a locus
on chromosome 6 in which velocity time integral associates with
aorta diameter (Figure 2C).
Significant QTL for serum lipid levels were identified on
chromosome 4 (HDL cholesterol; QTL peak=49 cM; maximum
LOD=5.0), chromosome 6 (LDL cholesterol; QTL peak=52 cM,
maximum LOD=6.3), and chromosome 8 (triglyceride; QTL
peak=5 cM, maximum LOD=4.9). In addition to the trait QTL
identified above, additional loci were mapped for the broad trait
areas of blood analytes/potassium on chromosome 9 (QTL
peak=0 cM; maximum LOD=5.1), and bone on chromosomes
10 and 14 (BMD; QTL peak=60 cm and 13 cm, respectively;
maximum LOD=5.0 and 4.3, respectively). It is noteworthy that
we did not detect genome-wide significant QTL (LOD$4.3/
FDR=0.10) for all of the traits measured in the B6AF2 cohort. In
particular,wedidnot detectsignificantQTLforanyoftheIPIST or
Oxymax measurements or for serum measures of glucose, insulin,
creatinine, chloride, sodium, and urea in analyses that included
both genders, although suggestive QTL (LOD.3.0) were identified
in these analyses and significant QTL were identified in the gender-
specific analyses (Table S2).
Mapping of eQTL in liver, adipose, kidney medulla, and
kidney cortex
Whole genome expression data were generated for all F2
progeny for four different tissues (gonadal adipose, liver, kidney
Networks and Metabolism
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Trait classification Trait Name Sub-trait Name
Time-
point Chr
QTL
Peak
(cM) LOD Ref
Adiposity Mesenteric Fat % Mesenteric Fat W16 6 35 4.6 [21]
Adiposity Mesenteric Fat % Mesenteric Fat W16 8 34 6.7
Adiposity Mesenteric Fat % Mesenteric Fat W16 16 2 4.3
Adiposity Subcutaneous Fat % Subcutaneous Fat W16 2 26 4.4
Adiposity Subcutaneous Fat % Subcutaneous Fat W16 8 34 6.1
Adiposity Total Fat % Total Fat (DEXA) W15 2 21 4.8
Adiposity Total Fat % Total Fat (DEXA) W15 6 34 5.6 [21]
Adiposity Total Fat % Total Fat (DEXA) W15 8 43 8.9
Adiposity Gonadal Fat Absolute Gonadal Fat W16 6 33 4.6 [21]
Adiposity Gonadal Fat Absolute Gonadal Fat W16 8 34 10.9
Adiposity Mesenteric Fat Absolute Mesenteric Fat W16 6 36 6.7 [21]
Adiposity Mesenteric Fat Absolute Mesenteric Fat W16 8 34 6.4
Adiposity Mesenteric Fat Absolute Mesenteric Fat W16 16 2 6
Adiposity Subcutaneous Fat Absolute Subcutaneous Fat W16 6 33 5.9 [21]
Adiposity Subcutaneous Fat Absolute Subcutaneous Fat W16 8 34 6.3
Adiposity Total Fat Absolute Total Fat (DEXA) W15 6 34 6.6 [21]
Adiposity Total Fat Absolute Total Fat (DEXA) W15 8 43 5.6
Blood Analytes Potassium Potassium W16 9 0 5.1
Blood Pressure Heart Rate Heart Rate W10 1 49 4.5
Blood Pressure SBP Systolic Blood Pressure W10 1 56 4.8 [10,18]
Bone BMD Bone Mineral Density W15 10 60 5
Bone BMD Bone Mineral Density W15 14 13 4.3
Echocardiographic Aorta Diameter Aorta Diameter W10 6 42 5.3
Echocardiographic Velocity Time Integral Velocity Time Integral W10 2 53 5.4
Echocardiographic Ejection Fraction Ejection Fraction W10 17 13 4.5
Glucose/Insulin OGTT OGTT AUC W13 6 47 5.6 [65]
Glucose/Insulin OGTT OGTT Glucose Change (0–15 min) W13 8 31 6.1
Leanness Lean mass % Lean Mass (DEXA) W15 2 21 4.5
Leanness Lean mass % Lean Mass (DEXA) W15 6 33 5.8 [21]
Leanness Lean mass % Lean Mass (DEXA) W15 8 43 8.7
Lipids HDL HDL Cholesterol W16 4 49 5 [66]
Lipids LDL LDL cholesterol W16 6 52 6.3
Lipids Triglyceride Triglyceride W16 8 36 4.9
Size Heart Heart weight/Body weight W16 6 30 7.7
Size Heart Heart weight/Body weight W16 8 49 8.1
Size Heart Heart-Left ventricle weight/BWt W16 8 34 6.8
Size Kidney Kidney weight/Body weight W16 8 34 16.1
Size Kidney Kidney weight/Body weight W16 16 6 4.6
Size Liver Liver weight/Body weight W16 8 32 13.8
Size weight Weight W6 1 64 4.8
Size weight Weight W7 6 31 5.1 [21]
Size weight Weight W8 1 64 4.4 [20]
Size weight Weight W10 1 71 4.5
Size weight Weight W10 6 31 4.7 [21]
Size weight Weight W12 1 64 5.1
Size weight Weight Change W6-W16 W16 1 78 4.5
Size weight Weight Change W6-W16 W16 6 47 5.8 [21]
Size weight Weight Change W6-W16 W16 8 43 4.4
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containing ,40,000 unique reporter sequences. Each reporter
sequence was individually considered as a trait for each tissue and
used to map expression QTL (eQTL). The distribution of LOD
scores by tissue is shown in Figure S4A. eQTL were considered
as cis acting QTL if the QTL mapping position lay within
+/220 Mb of the physical gene location. The bin size for
consideration of cis acting eQTL was similar to those used in
previous studies and was derived from the data in Figure S4B,
which show a significant increase in the number of eQTL detected
within 20 Mb of the associated gene only when the gene and QTL
reside on the same chromosome. A list of all eQTL with LOD$5,
corresponding to an FDR,0.05 in all tissues, is given in Table S3
(all animals), Table S4 (males only), and Table S5 (females only).
We also assessed the degree of sharing of eQTLs between tissues
(Table S6). In order to do this we defined eQTL at a reporter,
chromosome, tissue level (that is an eQTL was counted once as the
maximum LOD .=5 for any particular reporter, chromosome,
tissue group). Pairwise comparison of tissues shows greatest sharing
of eQTLs for the kidneycortex:kidneymedulla comparison (38.4%
cis, 11.9% trans). Overall there is much greater consistency of cis
eQTLs between tissues (average=27.6%) than trans eQTLs
(average=8.9%), consistent with previous observations.
An adipose trans eQTL signature drives the body
composition QTL on chromosome 8 in the B6AF2
population
Inspection of the eQTL distribution across chromosomes for
different tissues identified an eQTL hotspot in adipose between 30
and 40 cM on chromosome 8, as shown in Figure S5 (expected
number of eQTL in 10 cM interval=62; actual number =1722;
P=2.5e
2321). While trans eQTL hotspots can result from artifacts
we do not believe this is the case for this signature for three
reasons. First, when we permute the eQTL data and plot the
eQTL numbers per 10 Mb genomic bin across the genome we
never see more than 38 eQTL per bin, compared with .1000 in
the observed data for the chromosome 8 region (Figure S6).
Second, if it was the result of population substructure in the
intercross population we would anticipate seeing an enrichment of
eQTL at this locus across tissues while we actually observe that the
hotspot is specific to adipose (Figure S5). Most importantly, we
have been able to replicate this finding in an independent B6AF2
cohort of comparable size (‘‘Jaxshort BxA’’). Specifically we find
that of the 1,565 eQTLs (LOD.=5) in the MCI BxA signature at
the chromosome 8 locus that are trans (gene and QTL on different
chromosome), 1,491 (95%) replicate on chromosome 8 in the
Jaxshort BxA cohort at a LOD.=2. With more stringent
replication criteria, that requires LOD.=3 and maximum
QTL LOD position in the 30–40 cM interval, 929 (59%) eQTL
replicate. Comparison of the LOD scores for the eQTLs mapping
to chromosome 8 in adipose in the two crosses shows significant
correlation (R2=0.25, p=7.8e-96; Figure S7) and comparable
location (Figure S8). In the Jaxshort BxA cross the hotspot is
specific to adipose, as it is in MCI BxA; in this case specificity is
compared to liver, muscle and hypothalamus. This replication
data for the Jaxshort BxA cross is included as a series of tables
containing the gene expression data for the chromosome 8 eQTL
genes (Table S7), the genotypes for all animals (Table S8), the
Trait classification Trait Name Sub-trait Name
Time-
point Chr
QTL
Peak
(cM) LOD Ref
Size weight Weight Change W6-W16 W16 16 2 5.9
Size weight Weight Change W12-W16 W16 1 64 6.2
Size weight Weight Change W12-W16 W16 6 42 4.9 [21]
QTL Peak is the map position corresponding to the maximum LOD score.
doi:10.1371/journal.pone.0014319.t001
Table 1. Cont.
Figure 1. QTL hotspots for body composition, insulin, and glucose traits on chromosomes 6 and 8. QTL plots for traits mapping to
chromosome 6 (A) and chromosome 8 (B) indicate that shared DNA variation likely drives multiple metabolic phenotypes on the respective
chromosomes. For clarity not all significant QTL mapping to these loci are shown (see Table 1).
doi:10.1371/journal.pone.0014319.g001
Networks and Metabolism
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convincing evidence that the trans eQTL hotspot is unlikely to be
an artifact.
More than 95% of the eQTL at this locus are trans eQTL,
therefore we refer to this as the "trans8_eQTL" signature. This
location coincides with the position of the body composition QTL
hotspot (Figure 1B). To explore whether the trans8_eQTL
signature influences these traits we looked at the relationship
between the expression of genes in the signature in adipose tissue
and various endpoints. The first principal component of the
trans8_eQTL signature was computed (ch8PC1) and correlated to
the trait values across the population. The correlation coefficients
and associated P values are shown in Table 2. These data indicate
significant correlation of the trans8_eQTL signature with a
number of the traits at this locus. This correlation structure could
be the result of gene expression traits driving the clinical traits in a
causal relationship, or alternatively the gene expression changes
could lie downstream of the variation in the clinical traits. To
distinguish these possibilities we specifically looked for enrichment
of gene expression traits that tested as causal for the individual
clinical traits at this locus using a previously described causality test
[5]. We calculated the fold enrichment for genes testing causal for
a trait at this locus compared with across the genome by
computing the number of reporter_ids from the chromosome 8
eQTL signature testing causal for trait/total reporter_ids in the
chromosome 8 eQTL signature as a ratio to the total number of
reporter_ids testing causal for the trait/total number of reporter_-
ids on the array and used Fisher’s exact test to estimate the
significance of these enrichments. In this way we identified
enrichments for causal genes linked to metabolic traits in the
trans8_eQTL signature of up to 18.6-fold with highly significant
associated p values (Table 2 and Table S10). For example, 75% of
the reporters on the array chip that are expressed in adipose and
test causal for % mesenteric fat are present in the trans8_eQTL
signature (243 reporters out of 322 genome-wide total testing
causal for this trait: Table S10).
Annotation ofthetrans8_eQTLsignature byenrichment analysis
relative to genes in the Gene Ontology (GO) catalogue indicates
that these genes are strongly associated with cellular metabolic
processes,particularlyoxidativephosphorylationand mitochondrial
function (Figure S9). The idea that the genes in this signature relate
to mitochondrial function is further supported by the observation
that 307 out of 1537 signature genes are also found in a set of 1098
genes whose protein products have been shown localize to
mitochondria (enrichment p value=3.36e
2144) [23]. We also
mapped the signature to gene co-expression networks. Gene co-
expression network analysis (GCENA) has been used to identify
gene subnetworks and to prioritize gene targets associated with a
variety of common human diseases such as cancer and obesity [24–
28]. One important end product of GCENA is the construction of
gene modules comprised of highly interconnected genes, and a
number of studies have demonstrated that co-expression network
Figure 2. QTLs associated with blood pressure, heart rate, and echocardiography traits highlight different aspects of
cardiovascular physiology. QTL plots showing LOD scores by chromosomal position for the indicated traits. (A) locus on chromosome 1
associated with variation in blood pressure and heart rate; (B) locus on chromosome 2 associated with left ventricular anatomy and function and its
relationship to cardiac output; (C) locus on chromosome 6 regulating cardiac output parameters associated with aorta diameter.
doi:10.1371/journal.pone.0014319.g002
Networks and Metabolism
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genes that are linked to common genetic loci, and for genes
associated with disease [24–32]. The topological overlap map of the
MCI BxA adipose is shown in Figure S10. Intersection of the genes
from the trans8_eQTL signature indicates that they are very highly
enriched in the red (9.4-fold enriched; p=1.13E
2132) and turquoise
(2.2-fold enriched; p=1.14E
226) modules of the co-expression
network. Indeed,70%ofthegenesintheredmoduleareregulated
by the chromosome 8 locus indicating this is a key genetic driver of
this subnetwork. Annotation of these modules shows that the red
network is negatively correlated with adiposity traits and is enriched
in GO terms associated with a variety of catabolic and metabolic
processes and with mitochondrial function. The turquoise module is
positively correlated with adiposity traits and is linked to a diverse
set of biological processes including angiogenesis, apoptosis, cell
cycle, and immune cell activation (Figure S10).
We sought also to place this signature in the context of datasets
relevant to human obesity. In this context, the trans8_eQTL
signature shows strong enrichment in a human adipose co-
expression network module that we previously demonstrated to be
associated with BMI in humans (Figure S11) [25]. Specifically,
genes in the trans8_eQTL signature map to two expression
modules in the human adipose connectivity map. The red module
consists of genes involved in mitochondrial function while the
turquoise module is enriched for genes associated with immune
response. Both modules show correlation with metabolic traits
(leptin, BFM, BMI, HDL cholesterol, waist, and weight) and the
turquoise module has been identified as a key driver of obesity
traits in humans [25]. Together, these data support a role for the
chromosome 8 locus in driving adiposity phenotypes via effects on
energy metabolism and through genes and networks that are
conserved in mouse and human.
Validation of effects of chromosome 8 trans eQTL
signature genes on obesity traits
We selected three genes from the trans8_eQTL signature for
validation experiments in knockout mice. These genes were
selected based on a number of criteria, including causality for
adiposity traits based on the trans eQTL in the B6AF2 cohort,
causality for adiposity traits across other F2 crosses [5,6,33], and
availability of genetically modified mice. It is noteworthy that
Akr1b8, Emr1, and Rgs2 are in the top 5% of genes testing causal
for obesity traits in our database.
We first looked at the response to dietary challenge by
maintaining knockout mice and wild-type littermate controls on
a high-fat diet (HFD) for 9 weeks and recording changes in body
weight. The Rgs2 line showed statistically significant genotypic
differences in body weight gain in response to a HFD (Figure 3
and Table S11). This is consistent with the causality prediction of
an effect of Rgs2 on body weight (Table 3). Both male and female
Rgs2 knockout mice gained less weight than littermate controls
after 9 weeks of HFD (67% v 86% for males, p=2.8e
24; 32% v
52% for females, p=5.7e
23). These effects do not appear to be the
consequence of lower food intake, suggesting a mechanism linked
to energy metabolism rather than to hypophagia (data not shown).
We also compared the body composition of knockout and wild-
type mice measured by qNMR at two time-points, before and after
HFD feeding (Figure 4 and Table S12). We observed that the
Rgs2
2/2 mice gained less overall weight on HFD and that the male
knockout mice were leaner than the wild-type mice (37.6+/22.1%
fat versus 40.5+/21.2% fat; p=2.6e
23). The female Rgs2 mice did
not show a statistically significant difference between the genotypic
groups in body composition after HFD. A similar sexual
dimorphism towards a male effect was seen in the Akr1b8
2/2
strain, although in this case the tendency was for the male knockout
mice to be fatter than their wild-type littermate controls on both
chow (13.0+/22.1% fat versus 10.1+/21.6% fat; p=4.4e
23)a n d
HFD (41.7+/21.5% fat versus 36.4+/24.6% fat; p=4.9e
23)
(Figure 4 and Table S12). The male Akr1b8
2/2 mice also had
higher serum cholesterol levels after HFD (7.50+/20.58 mmol/L
versus 6.33+/20.76 mmol/L; p=2.0e
23) reflecting increases in
both HDL and LDL cholesterol (Table S13). The Emr1
2/2 strain
showed larger effects in the female than the male mice, with the
knockout showing a strong tendency to be leaner, particularly in
response to a HFD (22.0+/24.6% fat versus 32.2+/25.0% fat;
p=5.2e
24). Overall, these data validate our predictions from
Table 2. Association of eQTL signature to trait QTL on chromosome 8.
Sub-trait Name Correlation to PC Correlation p value
Fold enrichment for
causal genes
Enrichment
p value
% Total Fat (DEXA) 0.61 1.4E-31 7.5 7.7E-24
Absolute Gonadal Fat 0.58 8.5E-28 13.3 2.7E-42
Absolute Total Fat (DEXA) 0.54 8.2E-24 12.4 8.7E-144
% Mesenteric Fat 0.50 3.7E-19 18.6 3.3E-176
% Subcutaneous Fat 0.50 1.6E-18 16.5 2.6E-154
Absolute Mesenteric Fat 0.48 1.7E-18 9.7 2.5E-147
Absolute Subcutaneous Fat 0.47 7.4E-18 8.6 1.5E-95
Weight Change W6-W9 0.42 9.0E-14 14.6 7.3E-41
Triglyceride 0.34 3.0E-09 14.0 3.1E-273
Heart weight/Body weight 20.53 1.0E-22 1.4 3.0E-01
OGTT Glucose Change (0–15 min) 0.24 3.4E-05 12.0 2.9E-11
% Lean Mass (DEXA) 20.62 3.4E-32 7.2 1.1E-20
Fold enrichment obtained by calculating: (# reporter_ids from ch8 eQTL signature testing causal for trait/total reporter_ids in ch8 eQTL signature)/(total # reporter_ids
testing causal for trait/total reporter_ids on array).
Enrichment p value is from Fisher’s exact test.
PC=1st principal component for chromosome 8 eQTL signature.
doi:10.1371/journal.pone.0014319.t002
Networks and Metabolism
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traits in mice (as summarized in Table 3). Specifically, our genetic
analysis indicated a causal relationship between Akr1b8, Emr1, and
Rgs2 expression level and measures of body adiposity, with a
negative correlation between Akr1b8 expression in adipose and %
fat, and a positive correlation between Emr1 and Rgs2 expression
and % fat. All of these predictions were recapitulated in knockout
mice, in which loss of Rgs2 led to increased % fat and loss of Emr1 or
Rgs2 to decreased % fat. These data also underscore the strong
influence of gender on metabolic traits in mice, an observation we
have previously noted [34].
We also analyzed the transcriptional consequences of knocking
out the Akr1b8 and Rgs2 genes; unfortunately tissues were not
available from the Emr1
2/2 mice for profiling analysis. Specifically
we sought to explore whether the adipose knock out signatures
from these mice were enriched in the network modules
corresponding to the trans8_eQTL signature, namely the red
and turquoise modules that show strong correlation with adiposity
traits (Figure S10). This analysis (Table S14) indicates that the
gene expression signature in adipose associated with deletion of the
Akr1b8 gene is very significantly enriched specifically in the
turquoise module (fold enrichment=1.77-fold; hypergeometric
P value=0) but not in the red module (fold enrichment=1.02-
fold; hypergeometric P value =0.49). The Rgs2 signature shows
modest fold enrichments in both the turquoise (fold enrich-
ment=1.21-fold; hypergeometric P value=0.004) and the red
(fold enrichment=1.45-fold; hypergeometric P value=0.02)
modules although it only reaches significance P,0.01 in the
Figure 3. Growth Curves for Akr1b8
2/2, Emr1
2/2 and Rgs2
2/2 mice. Akr1b8, Emr1 and Rgs2 knockout (n=9 per gender)* and littermate control
(n=9 per gender)
# mice were placed on HFD at 9, 11, and 9 weeks of age respectively (W1 above). Body weights were recorded weekly for a total of
9 weeks. Statistically significant differences between genotypic groups split by gender are marked. Blue =WT males; Black =KO males; Red=WT
females; Green = KO females. *actual number of Emr1
+/+ female mice =8.
#actual number of Rgs2
2/2 female mice=6.
doi:10.1371/journal.pone.0014319.g003
Table 3. Summary of Causality and Knockout Phenotype Data for Akr1b8, Emr1, and Rgs2.
Knockout Phenotypes
Gene
Symbol
Traits for which genes test
causal based on eQTL/cQTL
overlap
Direction of
correlation of
expression to
trait
Change Body
Weight on HFD
Body Composition
on chow or HFD Serum Lipid
Akr1b8 % gonadal fat negative No difference KO v WT
for males or females
Increased % Fat in KOs
on chow or HFD compared
to WTs (males)
Increased serum
cholesterol in KOs on
HFD compared to WTs
(males)
Emr1 Weight, Absolute Subcutaneous adipose,
Absolute gonadal adipose, Absolute
mesenteric adipose, weight change W6-W12
positive No difference KO v WT
for males or females
Decreased % Fat in KOs
on chow or HFD
compared to WT (females)
No difference in serum
lipids KO v WT for males
or females
Rgs2 Weight, Absolute Total Fat, % Total Fat, %
subcutaneous adipose, Absolute mesenteric
adipose, absolute gonadal adipose
positive Male and female KO
mice gain less weight
on HFD
Decreased % Fat in KOs
in response to HFD
compared to WT (males)
Increased serum
cholesterol in KOs on
chow compared to WTs
Rgs2 % Lean Mass (DEXA) negative Male and female KO
mice gain less weight
on HFD
Decreased % Fat in KOs in
response to HFD compared
to WT (males)
Increased serum
cholesterol in KOs on
chow compared to WTs
doi:10.1371/journal.pone.0014319.t003
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Akr1b8 and Rgs2 genes are important regulators of adiposity in the
mouse and that their perturbation leads not only to predicted
metabolic changes in the mouse but also to changes in the
transcriptional networks in which they operate.
Trans8_eQTL signature is enriched for genes that show
association to T2D in human GWAS
In addition to being linked to adiposity traits, the trans eQTL
signature is associated with endpoints relevant to diabetes, namely
glucose traits (Table 1, Table S2, and Figure S2). We reasoned
that if this set of genes is important in human disease, SNPs linked
to these genes would show enrichment of association with
particular disease phenotypes. Toward this end, we identified
human eSNPs (SNPs that significantly associate with expression
traits) corresponding to the orthologous human genes from the
trans8_eQTL signature using data from a genetics of gene
expression (GGE) study in an obesity cohort comprised of 800
individuals from which liver, subcutaneous, and omental adipose
tissues were collected (Zhong, H. et al. Elucidating Networks of
eSNPs Associated with Type 2 Diabetes. Submitted). To test
whether the eSNPs were enriched for association to type 2 diabetes
(T2D), we assembled GWAS results from the meta-analysis of
multiple T2D cohorts, referred to here as the DIAGRAM study
[35].
Among the 1537 genes, 1249 have human orthologs, of which
502 have at least one eSNP in adipose tissue. The distribution of
their T2D association P values from the DIAGRAM (referred to
here as PT2D) is shown in Figure S12. It is apparent that the
PT2D distribution of the eSNPs associated with genes in the
trans8_eQTL signature is enriched for SNPs associated with T2D,
in that the eSNP PT2D values are skewed towards the significance
end of the PT2D spectrum. To statistically estimate the degree of
enrichment and associated significance, we empirically estimated
the null distribution by randomly sampling 100,000 sets of SNPs
from the DIAGRAM data such that the SNP set size, the location
distribution of the SNPs with respect to protein coding genes, the
linkage disequilibrium structure, and the minor allele frequency
matched that of the eSNP set (Methods S1 and Materials and
Methods). We found that 6.85% of SNPs in the eSNP set (460 out
of 6,720 SNPs) had PT2D values ,0.05, compared with an average
of 5.62% SNPs (95% CI: 5.01% to 6.17%) in the random sets
(Z=4.38; P=6.0e
206). It is of note that the eSNP sets
corresponding to the trans8_eQTL signature generated from
subcutaneous and omental adipose tissue separately were both
enriched for lower PT2D values: for the omental adipose 394 SNPs
out of 5,639 SNPs (6.99%) had PT2D values ,0.05; for the
subcutaneous adipose 338 SNPs out of 4,841 SNPs (6.98%) had
PT2D values ,0.05 (data not shown). Therefore, this enrichment is
consistently observed for the trans8_eQTL signature.
Discussion
This study contributes significantly to our knowledge of QTL in
mouse that genetically regulate traits relevant to metabolic and
cardiovascular disease, as well as hypertension. Furthermore, the
tissue gene expression data provided in this paper provide a
powerful framework for relating DNA variation to gene expression
changes, and in turn to phenotypic variation. We have shown how
this can be applied to help elucidate the molecular mechanisms
underlying complex trait variation in the context of a chromosome
8 adiposity QTL.
The emphasis of our approach is not to directly define the cis
variants that underlie QTL but rather to understand how this
variation drives changes in entire networks of genes that regulate
physiological processes. For example, it is unclear from our
analysis what the underlying perturbation(s) on chromosome 8
that drive the trans8_eQTL signature are, but it is apparent that
the genes whose expression traits map here in trans are the
molecular effectors of the cis signal. We have shown this by
demonstrating: a) that the adipose expression of genes in the
trans8_eQTL signature is highly correlated with the adiposity-
related traits; b) that the genes test causal for driving variation in
the adiposity traits; c) that the genes map to modules in human
adipose that have been implicated in human obesity; and d) by
validating three of the genes in the signature by phenotyping
knockout mice.
Figure 4. Body Composition by qNMR for Akr1b8
2/2, Emr1
2/2 and Rgs2
2/2 mice on chow and HFD. Body composition for Akr1b8, Emr1
and Rgs2 knockout and littermate control mice was assessed on chow diet (8–10 weeks of age) and after 9 weeks on HFD (17–23 weeks of age). Data
points are averages with 95% confidence intervals. Statistically significant differences between genotypic groups split by gender are marked. All
gender, genotype, diet groups were n=9 except for the female Emr1
+/+ HFD fed and female Rgs2
2/2 chow fed groups were n=8.
doi:10.1371/journal.pone.0014319.g004
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existing datasets strongly suggests that the mechanism underlying
the effects of the chromosome 8 DNA variation on adiposity
relates to energy expenditure. The genes in the signature are
highly enriched for metabolic processes associated with generation
of precursor metabolites, oxidative phosphorylation, and mito-
chondrial ATP synthesis. Remarkably, 20% of the genes are found
within a curated set of 1090 genes with protein products predicted
to be located in the mitochondrion [23]. Given that the curated
mitochondrial gene set is highly unlikely to be comprehensive, the
true fraction of the genes in the trans8_eQTL signature that
localize to the mitochondrion is likely to be much higher. In this
context it is interesting to note that one of the cis acting candidates
at the chromosome 8 locus is Fto, a gene that has been robustly
validated for association with human obesity [36–38] and has
recently been implicated in regulating energy expenditure in mice
[39]. Fto
2/2 mice show significantly elevated oxygen consumption
(V02), carbon dioxide production (VCO2), and calculated heat
production (Heat) relative to their wild-type littermates. Consistent
with an Fto driven mechanism underlying the chromosome 8
locus, there are highly suggestive QTL at this locus for traits
associated with energy metabolism (Figure S2 and Table S2). FTO
is also associated with T2D in human populations [40–42]. In this
regard it is interesting that we were able to demonstrate that genes
in the signature show greater association with T2D than similar
sets of randomly selected genes (Figure S12). An alternative
candidate gene on chromosome 8 that has a well-established role
in adiposity and mitochondrial function is Ucp1[43]; however, we
did not detect a significant cis eQTL for Ucp1 in B6AF2 adipose,
nor are there known non-synonymous SNPs in the gene between
these two strains. Furthermore, we detected a significant adipose
cis eQTL for Ucp1 in a C57BL/6J ob/ob vs. BTBR ob/ob F2 cross
[44] but this cis eQTL is not associated with the trans8_eQTL
signature or a significant adiposity QTL on chromosome 8. We
conclude that Fto is a good candidate for explaining the
chromosome 8 adiposity QTL although additional studies into
Fto perturbation in mice will be necessary to validate this
connection.
We have shown experimentally the effects of deleting three
genes regulated by the chromosome 8 locus on adiposity traits in
knockout mice. These genes are Emr1, Rgs2, and Akr1b8, and the
associations with metabolic phenotypes represent novel findings.
Emr1 is the prototypical macrophage lineage marker in the mouse,
although its tissue distribution appears to be different in humans
[45]. It is a seven-membrane spanning molecule (TM7) and,
together with CD97, EMR2, EMR3, and EMR4, belongs to the
EGF-TM7 family, a subfamily within the adhesion class of TM7
receptors [46]. Although these receptors have variable numbers of
EGF-like domains that can mediate ligand binding, a cellular
ligand for Emr1 has not yet been identified. Emr1-deficient mice
are healthy and do not show abnormalities in macrophage
development and function [46]. Rgs2 acts downstream of TM7
proteins to regulate and integrate G-protein coupled signaling
[47]. Specifically, RGS2 is a selective and potent inhibitor of Gaq
signaling [48], is ubiquitously expressed throughout the cardio-
vascular system, and is capable of inducing adipocyte differenti-
ation [49]. Rgs2-null mice are hypertensive [50–52] and
polymorphisms in RGS2 have been implicated in human
hypertension [53,54]. More recently, RGS2 variation has been
associated with metabolic syndrome and weight gain in humans
[55,56]. Akr1b8 is a member of the aldo-keto reductase (AKR)
superfamily encompassing more than 140 proteins with different
physiological roles, most of which are NAD(P)(H)-dependent
oxidoreductases that metabolize carbohydrates, steroids, prosta-
glandins, and other endogenous aldehydes and ketones, as well as
xenobiotic compounds. This family is thought to play physiological
roles in osmotic homeostasis, steroid and xenobiotic metabolism,
signal processing, and oxidative defense mechanisms [57]. All
three of these genes show association with the trans8_eqtl
signature and each displays a unique pattern of metabolic
dysfunction when knocked out in mice.
In addition to the chromosome 8 eQTL hotspot in adipose
there are other potential hotspots in other tissues. For example,
there is an enrichment of eQTLs on chromosome 6 in liver, on
chromosome 18 in liver and kidney cortex, on chromosome 1 in
liver and adipose, and on chromosomes 4 and 13 in kidney cortex
and kidney medulla (Figure S5). While all of these are significant
with respect to the permuted eQTL data we have been unable to
replicate them in an independent cohort in the same way as we
have demonstrated for the chromosome 8 adipose eQTL hotspot;
the chromosome 6 liver eQTL hotspot is present in the Jaxshort
BxA cohort but is much weaker. Therefore at this point it appears
that strong replicating eQTL hotspots are uncommon, at least
those containing eQTLs with effect sizes that we are powered to
detect with F2 cohorts of 300–500 animals.
In conclusion we believe that the data contained in this paper,
including the eQTL for the four tissues– adipose, liver, kidney
cortex, kidney medulla – as well the trait QTL, will be a rich
source of information for the community in ongoing research to
identify the genes and networks associated with metabolic and
cardiovascular disease.
Materials and Methods
Ethics Statement
All mouse procedures were performed with the approval of
Merck & Co (Whitehouse Station, NJ, USA) and the Institutional
Animal Care and Use Committees at the Jackson Laboratories
(Jax West, West Sacramento, California) or Mouse Clinical
Institute (MCI: Strasbourg, France) as appropriate under IACUC
approval 07-254.
Mouse breeding, husbandry, and physiological trait
measurements
Additional detail on mouse study design and procedures is
available in the complete study protocol in Methods S1. In
general, the SOPs in this study were modeled on those of the
Eumorphia program (www.empress.har.mrc.uk). All procedures
were performed with the approval of Merck & Co (Whitehouse
Station, NJ, USA) and the Institutional Animal Care and Use
Committees at the Jackson Laboratories (Jax West, West
Sacramento, California) or Mouse Clinical Institute (MCI:
Strasbourg, France) as appropriate.
All F2 breeding was performed at JAX West (Sacramento, CA),
and knockout animals were bred at Taconic Farms (Germantown,
NY). Three hundred and sixty F2 mice were produced from a
C57BL/6J (female) x A/J (male) cross (B6AF2). F1 mice (n=12 of
each gender) and parental strain mice (n=12 of each strain and
gender) were tested in parallel at the same age under the same
conditions. Mice were weaned into cages of three same-sex pups
per litter per cross at 3 weeks of age. These three littermate mice
remained together for the duration of the study. At 6 weeks, mice
were shipped by air to MCI and allowed to acclimate to that
environment for 1 week before entering the study. Twenty-four F2
mice entered MCI every week for 18 weeks, except for weeks 1, 3,
and 16, when eight each of the parental and F1 mice entered.
An overview of the experimental protocol is provided in Figure
S1. Mice were weighed after arrival at week 6, and switched to a
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kcal from fat, and a potassium and sodium concentration per kcal
that is identical to that found in the standard D12450B diet, which
provides 10% kcal from fat. All diets were prepared by Research
Diets (New Brunswick, NJ). Body weight was measured weekly
through week 12, with blood pressure measurement by tail cuff on
a BP-2000 Blood Pressure Analysis System (Visitech Systems Inc,
Apex, NC) in week 10. The mice also received a complete
echocardiographic exam (Sonos 5500, Philips Electronics, Kon-
niklijke, Netherlands) at the end of week 10 after completing the
blood pressure measurements. The mice were assayed in an
Oxymax metabolic chamber in week 12, underwent an overnight
fast (16–18 h) followed by an Oral Glucose Tolerance Test
(OGTT) in week 13, an Intra-Peritoneal Insulin Sensitization Test
(IPIST) in week 14, and a Dexascan procedure in week 15. In
week 16, mice were fasted for 4 hours prior to CO2 asphyxiation
and necropsy. Detailed SOPs for these protocols are listed in the
Methods S1.
Genotyping
Genomic DNA was isolated from tail sections by Bioserve
(Beltsville, MD) using standard methods and genotyping was
performed by Affymetrix (Santa Clara, CA) using the Affymetrix
GeneChip Mouse Mapping 5K Panel.
Microarray analysis
RNA extraction, probe preparation, and array hybridizations
were all carried out at the Rosetta Inpharmatics Gene Expression
Laboratory (Seattle, WA). Mouse tissues (gonadal adipose, kidney
medulla, kidney cortex, hypothalamus) were pulverized prior to
homogenization in a solution of GITC/BME (1:50 ratio) using a
Covaris S2 cryo-prep (Covaris, Inc, Woburn, MA), followed by
addition of a TRIzol water solution (4:1 ratio). 100% Chloroform
was added to the TRIzol/GITC lysate (1:5 ratio) to facilitate
separation of the organic and aqueous components using the
phaselock (Eppendorf) system. The aqueous supernatant was
further purified using a Promega SV-96 total RNA kit (Promega,
Madison, WI), incorporating a DNase treatment. Total RNA
samples were assayed for quality using an Agilent Bioanalyzer
(Agilent Technologies, Santa Clara, CA) and for yield using
Ribogreen (Ambion, Austin, TX) metrics prior to amplification.
All samples, with the exception of kidney medulla, were amplified
and labeled using a custom automated version of a 5 mg RT/IVT
protocol and hybridizations to custom Agilent microarrays were
performed as described [58].
The custom ink-jet microarrays used in this study were
manufactured by Agilent Technologies and consisted of 4,732
control probes and 39,558 non-control oligonucleotides derived
from mouse Unigene clusters, combined with RefSeq sequences
and RIKEN full-length cDNA clones. For each individual animal
tissue sample, labeled complementary RNA (cRNA) was hybrid-
ized against a pool of labeled cRNAs constructed from equal
aliquots of RNA for that specific tissue from at least 200
individuals.
Gene expression profiling of Akr1b8
2/2, Rgs2
2/2 and control
wt mice was performed on Merck/Affymetrix mouse 1.0 custom
arrays monitoring 43,682 individual transcripts (28,782 Entrez
genes). Total RNA was isolated from frozen tissues after
homogenizing in TRIzol reagent (Invitrogen, Carlsbad, CA) and
processed using RNeasy kits (QIAGEN, Valencia, CA) according
to manufacturers’ instructions. Samples were amplified and
labeled using a custom automated version of the RT/IVT
protocol and reagents provided by Affymetrix (Santa Clara, CA).
Hybridization, labeling and scanning were completed following
the manufacturer’s recommendations (Affymetrix).
Allmicroarraydata isMIAMEcompliantandhasbeendeposited
in GEO with the following accession number: GSE25506.
QTL mapping and Network Construction
QTL mapping was performed using R/qtl [60], and testing for
linkage of both clinical traits and gene expression (using the mean
log ratio of the expression) was conducted using a linear model
[33,59]. Briefly, we first calculated QTL genotype probabilities,
conditional on the available marker data (‘‘calc.genoprob’’
function), and then used Haley-Knott regression (‘‘scanone’’
function) to perform single-QTL genome scans with a normal
model [60]. Specifically, each clinical and expression trait was
parameterized as:
y*b0zbALAizbDLDi
where y is the trait of interest, LAi=P ri(AA)-Pri(BB) is the additive
genotypic component at the ith locus and LDi=P ri(AB) is the
dominance genotypic component. For eQTL analyses, the gene
expression trait values were first pre-adjusted with gender as a
covariate in a linear model and the gender adjusted gene
expression trait residuals used as the dependent variable in the
QTL mapping. eQTL and cQTL mappings were also performed
in female and male samples separately using ‘‘non-gender
adjusted’’ values.
We conducted a permutation approach to compute False
Discovery Rate (FDR) for cQTL and eQTL. LOD scores of
cQTLs were empirically adjusted on a trait-by-trait basis using
1,000 permuted datasets. First, p-values were computed for each
LOD score on a trait-by-trait basis, using the LOD scores from
permuted data as the distribution under the null. LOD scores from
the permuted data were adjusted using the same approach. FDR
estimates were then computed by comparing the observed results to
the permuted. Using this approach, a LOD score of 4.3 for cQTL
corresponds to FDR 0.10 (Figure S13). FDR for eQTLs were
computed on a tissue by tissue level using five permuted datasets.
LOD scores from permuted data for all the probes were used as the
distribution under the null. A LOD score of 5 for eQTL
corresponds to an FDR ,0.05 for all four tissues (Figure S14).
For co-expression analysis, the 9,889 (the top 25%) most
differentially expressed genes were selected for constructing a
weighted gene co-expression network [30]. In contrast to
traditional un-weighted gene co-expression networks where two
genes (nodes) are either connected or disconnected, the weighted
gene co-expression network analysis assigns a connection weight to
each gene pair using soft-thresholding and thus is robust to
parameter selection. The weighted network analysis begins with a
matrix of the Pearson correlations between all gene pairs, then
converts the correlation matrix into an adjacency matrix using a
power function f(x)=x
b. The parameter b of the power function is
determined in such a way that the resulting adjacency matrix, i.e.,
the weighted co-expression network, is approximately scale-free.
To measure how well a network satisfies a scale-free topology, we
use the fitting index proposed by Zhang & Horvath [30], i.e., the
model fitting index R
2 of the linear model that regresses log(p(k)) on
log(k) where k is connectivity and p(k) is the frequency distribution
of connectivity. The fitting index of a perfect scale-free network is
1. For this dataset, we select the smallest b (=6)which leads to an
approximately scale-free network with the truncated scale-free
fitting index R
2 greater than 0.8. The distribution p(k) of the
resulting network approximates a power law: p(k)*k{1:63.
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the adjacency matrix is further transformed into a topological
overlap matrix. Topological overlap between two genes reflects
not only their direct interaction but also their indirect interactions
through all the other genes in the network, and previous studies
[30,61][30,62][28,60]have shown that topological overlap leads to
more cohesive and biologically more meaningful modules [30]. To
identify modules of highly co-regulated genes, we used average
linkage hierarchical clustering to group genes based on the
topological overlap of their connectivity, followed by a dynamic
cut-tree algorithm to dynamically cut clustering dendrogram
branches into gene modules. 35 modules are identified and the
module size, in number of genes, varies from 20 to 2,035.
To distinguish between modules, each module was assigned a
unique color identifier, with the remaining, poorly connected genes
colored grey. Figure S10 shows the hierarchical clustering over the
topological overlap matrix (TOM) and the identified modules for
the MCI BxA adipose. In this type of map, the rows and the
columns represent genes in a symmetric fashion, and the color
intensity represents the interaction strength between genes. This
connectivity map highlights genes in the adipose transcriptional
network that fall into distinct network modules, where genes within
a given module are more interconnected with each other (blocks
along the diagonal of the matrix) than with genes in other modules.
Likelihood-based causality model selection test and
causal gene enrichment test
Three basic relationships between genotypes, RNA levels and
complex traits are possible once the expression of a gene (R) and a
complex trait (C) have been shown to both correlated with a
common QTL (L) in an F2 intercross population: where L the
common locus is defined as the marker equidistant between the
overlapping QTL peaks. Model M1 is a causal relationship with
respect to R, in which L acts on C through transcript R. Model
M2 is a reactive model with respect to R, in which R is modulated
by C. Model M3 is the independent model, in which the QTL at
locus L acts on traits R and C independently. M1 implies L lead to
changes in trait R that in turn lead to changes in C; while M2 and
M3 imply the gene expression changes lie downstream of the
variation in the clinical traits or independently of the clinical traits
[5]. We applied a likelihood-based causality model selection
(LCMS) test that uses conditional correlation measures to
determine which relationship among traits is best supported by
the data [5]. The joint probability distributions corresponding to
these three models, respectively, are
M1: P L, R, C ðÞ ~P L ðÞ P RjL ðÞ P CjR ðÞ
M2: P L, R, C ðÞ ~P L ðÞ P CjL ðÞ P RjC ðÞ
M3: P L, R, C ðÞ ~P L ðÞ P CjL ðÞ P RjC,L ðÞ
where P(L) is the genotype probability distribution for locus L and
is based on a previously described recombination model [62]. The
random variables R and C are taken to be normally distributed
about each genotypic mean at the common locus L, so that the
likelihoods corresponding to each of the joint probability
distributions are based on the normal probability density function.
Likelihoods associated with each of the models are constructed
and maximized with respect to the model parameters, and the
model with the smallest Akaike Information Criterion (AIC) value
is identified as the model best supported by the data [63]. If M1 is
selected as the best model we conclude that the data suggests that
the gene expression trait is supported as causal for the clinical trait
[5]. In practice we applied the LCMS test as follows. On a tissue,
gender group basis we scanned the genome for cQTL and eQTLs
with LOD.=2, and then collected cQTL:eQTL genomic
overlaps each time we detected peaks that overlapped at the
LOD.1 threshold. These overlaps were subjected to the LCMS
procedure using a marker (L) for testing selected equidistant
between the overlapping QTL peaks. The statistics for these
overlaps and test results are given in Table S15.
We calculated the fold enrichment for genes testing causal for a
trait inthe chromosome 8eQTLsignature setcomparedwithacross
the genome by computing the fraction of causal reporter_ids in the
chr8-eQTL signature/the fraction of causal reporter_ids on the
array. The significance of the fold increase is estimated using
Fisher’s exact test statistics under the null hypothesis that the
frequency of the causal genes in the signature set was the same
between the whole reference set of genes on the array.
Statistical Methods for eSNP Enrichment
We used a random sampling strategy to assess whether a given
set of eSNPs was more likely to associate with T2D than
randomly selected sets of SNPs of equal number. In each random
sample, we randomly selected genotyped SNPs that were located
within 1 MB of human gene regions and that had minor allele
frequency (MAF) .4%, to ensure the location and MAF
distributions of the random SNP sets matched that of the eSNP
set of interest. The process was repeated 100,000 times. For each
random SNP set, we counted the percentage of SNPs with GWAS
p,0.05, P1
0:05 ...P
100,000
0:05 , and constructed the null distribution
based on these counts. By the central limit theorem, the null
distribution should approximately follow a normal distribution.
This was confirmed by direct observation. We then compared the
observed percentage of eSNPs with GWAS p,0.05 in the eSNP
set, Pobs
0:05, with the null distribution. We defined the Z statistic as
Z~
Pobs
0:05{  P P0:05 ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1
B{1
P B
1
(Pi
0:05{  P P0:05)
2
s , and the p value for enrichment at
the 0.05 level was thus calculated as W(Z), where W(:) is the
standard normal cumulative probability. Here we used the p value
derived from the normal distribution rather than defining it as the
percentage exceeding the observed P in the eSNP set from random
samples (P~
P B
1
1(Pi
0:05w~Pobs
0:05)
B
). We chose to report the
theoretical p values to increase the resolution of our results, since
over most of the testing few p values from the 100,000 random
samples were smaller than those for the observed eSNP sets. In
cases where the empirical p values were greater than zero, they
were consistent with the theoretical p values.
Methods for KO generation and phenotyping
Mice with inactivated Akr1b8, Emr1, and Rgs2 genes were
constructed by replacing coding regions in exon 1 of the genes
(Akr1b8,2 5n t ;Emr1, 71 nt; Rgs2, 83 nt) with a pGK-Neo cassette
that would both block further transcription and cause a frame shift
in any resulting mRNA. A detailed description of the Emr1 KO
generation is provided by Lin et al [64]. The Akr1b8 and Rgs2 null
mice were provided by Deltagen (San Mateo, CA). All three KO
mice strains were backcrossed to C57Blk6/N, the Akr1b8 and Rgs2
KO mice were backcrossed to N=6, while the Emr1 KO mice were
backcrossed to N=11. Mice were shipped to MCI for phenotyping.
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Akr1b8 (n=3) and Rgs2 (n=3) KO male mice and littermate
controls (n=3 per line). RNA was extracted and processed for
microarray as described above. Analysis of microarray data was
performed using a one-way ANOVA to compare the genotypic
groups (KO v WT) following normalization of the data with the
RMA algorithm. The results of this analysis are available in Table
S16. Enrichment analysis of the KO signatures versus the MCI BxA
F2adipose co-expression modules (FigureS10)was performedusing
Entrez Gene IDs (LLIDs) to match across platforms (Affymetrix to
Agilent). Unique IDs for each category were tallied and fold-
enrichment calculated with significance derived from the hypergeo-
metric P value (Table S14).
Supporting Information
Figure S1 Phenotyping platform and timeline for trait collection
in the B6AF2 cohort. - Mice were shipped from USA to France at
6 weeks of age, acclimatized for 1 week and then entered the study.
Mice were fed a modified high fat, salt balanced diet for the
duration of the study (9 weeks), and were subjected to phenotying
at the illustrated times. Details on the individual trait measures are
included in the methods and supplemental methods. Mice were
sacrificed at 16 weeks and tissues harvested for gene expression
profiling.
Found at: doi:10.1371/journal.pone.0014319.s001 (0.43 MB TIF)
Figure S2 Adiposity QTL hotspot on chromosome 8 coincides
with QTL for Energy and Glucose Traits. - QTL plots showing
adiposity, energy, and glucose traits mapping to chromosome 8.
Note that not all traits are shown for clarity. For additional
information on QTLs at this locus see Supplemental Table S2.
Found at: doi:10.1371/journal.pone.0014319.s002 (0.53 MB TIF)
Figure S3 Hierarchical clustering of traits across the mouse F2
population. - Trait values from the 360 individuals from the F2
population were normalized to allow comparison by converting to
Z-scores. They were hierarchically clustered using an UPGMA
unweighted average. Individual mice are represented as rows and
traits as columns. Red represents Z.2 and green Z,-2.
Found at: doi:10.1371/journal.pone.0014319.s003 (1.60 MB TIF)
Figure S4 eQTL tissue distributions and characterization of cis
versus trans eQTL. - (A) cis and trans eQTL LOD distribution
across tissues; (B) counts of eQTL (Y-axis) versus distance in bp
between gene and QTL position (X-axis) for genes that are
physically located on a different chromosome from the eQTL
(gray) or on the same chromosome as the eQTL (black).
Found at: doi:10.1371/journal.pone.0014319.s004 (1.21 MB TIF)
Figure S5 eQTL chromosomal distribution by tissue - adipose
(A), kidney cortex (B), kidney medulla (C), liver (D). - The count
indicated on the Y-axis refers to the number of unique
reporter_ids. Note the peak of eQTLs in the middle portion of
chromosome 8 specific to the adipose tissue (A). Other eQTL
hotpsots are apparent, notably a liver-specific eQTL signature on
chromosome 6.
Found at: doi:10.1371/journal.pone.0014319.s005 (1.18 MB TIF)
Figure S6 Frequency of eQTL Hotspots in Observed and
Permuted Data. The figure shows a frequency distribution for the
number of times a 10 Mb genomic bin contains a certain number
of eQTLs with LOD.5 (X-axis) for the observed and permuted
data from adipose. All four of the 10 Mb bins containing .1000
eQTLs in the observed data are from chromosome 8. The
maximum number of eQTLs seen in any 10 Mb bin across the
permuted data is 38 in Permute set 1.
Found at: doi:10.1371/journal.pone.0014319.s006 (0.14 MB TIF)
Figure S7 Plot of the MCI BxA adipose LOD scores versus the
Jaxshort BxA adipose LOD scores for trans eQTL from the
chromosome 8 hotspot. Shown are gene reporters that map to the
30-40 cM interval on chromosome 8 in the MCI BxA cohort and
the maximum LODs for the corresponding reporters in the
Jaxshort BxA cohort on chromosome 8.
Found at: doi:10.1371/journal.pone.0014319.s007 (0.15 MB TIF)
Figure S8 QTL maximum position on chromosome 8 for the
replicating trans eQTL in the Jaxshort BxA cross. This figure
illustrates that most of the eQTL map to a similar position (30–
40 cM interval) on chromosome 8.
Found at: doi:10.1371/journal.pone.0014319.s008 (0.08 MB TIF)
Figure S9 Mouse Trans8_eQTL signature is enriched in GO
Biological Process terms associated with energy metabolism,
oxidative phosphorylation and mitochondrial function. - The
hierarchical structure represents the relationship between GO
biological terms in the human Gene Ontology. The terms are
colored according to the degree of enrichment for genes in the
trans8_eQTL signature (red, P,10-30: mid pink, P,10-10: light
pink, P,10-6). Only terms with statistically significant enrich-
ments are shown (P,10-6).
Found at: doi:10.1371/journal.pone.0014319.s009 (1.73 MB TIF)
Figure S10 Mouse Trans8_eQTL signature maps to two
modules in the adipose co-expression network. - This figure shows
the topological overlap map for adipose from the MCI BxA
cohort. The trans8_eQTL signature is highly enriched in the red
and turquoise modules. These modules are highly correlated with
metabolic traits and associated with GO terms for mitochondria
and metabolic processes (red) and angiogenesis, apoptosis, cell
cycle, and immune cell function (turquoise).
Found at: doi:10.1371/journal.pone.0014319.s010 (1.68 MB TIF)
Figure S11 Mouse Trans8_eQTL signature maps to human
adipose modules whose expression correlates with metabolic traits.
- The human male adipose connectivity map is as previously
described [25]. The enrichment P values for the overlap of the
mouse trans8_eQTL signature to the red and turquoise modules
are given as well as the traits with which the modules correlate.
Gene ontology annotation of the genes in these modules is also
shown.
Found at: doi:10.1371/journal.pone.0014319.s011 (1.11 MB TIF)
Figure S12 SNP Set P value Distribution from DIAGRAM
GWAS. - The binned P values are shown on the X-axis for (A) the
full set of all SNPs with MAF .4% and (B) the set of 6,720 eSNPs
associated with adipose gene expression in the trans8_eQTL
signature.
Found at: doi:10.1371/journal.pone.0014319.s012 (0.72 MB TIF)
Figure S13 FDR by LOD score plot for cQTL.
Found at: doi:10.1371/journal.pone.0014319.s013 (0.00 MB
PNG)
Figure S14 FDR by LOD score plot for eQTL for Four Tissues;
Liver, Adipose, Kidney Medulla, Kidney Cortex.
Found at: doi:10.1371/journal.pone.0014319.s014 (0.00 MB
PNG)
Table S1 Trait values across the Parental, F1 and F2 cohorts.
Found at: doi:10.1371/journal.pone.0014319.s015 (0.03 MB
XLS)
Table S2 Trait QTL identified in the B6AF2 Cohort.
Found at: doi:10.1371/journal.pone.0014319.s016 (0.18 MB
XLS)
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genders.
Found at: doi:10.1371/journal.pone.0014319.s017 (5.93 MB
XLS)
Table S4 eQTL identified in the B6AF2 Cohort using Male
only.
Found at: doi:10.1371/journal.pone.0014319.s018 (3.59 MB
XLS)
Table S5 eQTL identified in the B6AF2 Cohort using Female
only.
Found at: doi:10.1371/journal.pone.0014319.s019 (3.84 MB
XLS)
Table S6 cis and trans eQTL sharing between tissues for eQTLs
LOD.=5.
Found at: doi:10.1371/journal.pone.0014319.s020 (0.02 MB
XLS)
Table S7 Corrected (batch and gender) Gene Expression Data
for 1722 reporter_ids representing the chromosome 8 hotspot in
the Jaxshort BxA Adipose Replication Cohort.
Found at: doi:10.1371/journal.pone.0014319.s021 (4.35 MB
CSV)
Table S8 Genotype Data for the Jaxshort BxA Replication
Cohort.
Found at: doi:10.1371/journal.pone.0014319.s022 (2.84 MB
CSV)
Table S9 Gender assignments for Jaxshort BxA replication
cohort.
Found at: doi:10.1371/journal.pone.0014319.s023 (0.04 MB
XLS)
Table S10 Enrichment Analysis for causal genes in trans8_-
eQTL signature.
Found at: doi:10.1371/journal.pone.0014319.s024 (0.02 MB
XLS)
Table S11 Body Weight data for Akr1b8-/-, Emr1-/-, and
Rgs2-/- and littermate controls.
Found at: doi:10.1371/journal.pone.0014319.s025 (0.03 MB
XLS)
Table S12 Body Composition data by qNMR for Akr1b8-/-,
Emr1-/-, and Rgs2-/- and littermate controls.
Found at: doi:10.1371/journal.pone.0014319.s026 (0.07 MB
XLS)
Table S13 Serum Lipid composition for Akr1b8-/-, Emr1-/-,
and Rgs2-/- and littermate controls.
Found at: doi:10.1371/journal.pone.0014319.s027 (0.05 MB
XLS)
Table S14 Enrichment of Akr1b8-/- and Rgs2-/- adipose
signatures in the MCI BxA F2 adipose co-expression modules
associated with the trans eQTL signature and adiposity traits.
Found at: doi:10.1371/journal.pone.0014319.s028 (0.02 MB
XLS)
Table S15 Number of cQTL:eQTL pairs tested for causal/
reactive/independent/no call relationship grouped by Tissue and
Gender.
Found at: doi:10.1371/journal.pone.0014319.s029 (0.03 MB
XLS)
Table S16 ANOVA Analysis of Akr1b8-/- (n=3) and Rgs2-/-
(n=3) adipose signatures versus littermate controls.
Found at: doi:10.1371/journal.pone.0014319.s030 (7.64 MB
XLS)
Methods S1
Found at: doi:10.1371/journal.pone.0014319.s031 (0.07 MB
DOC)
Acknowledgments
We would like to thank Sonia Carlson for Project Management, Solly
Sieberts for help with QTL methods and Mary Derry for editing of the
manuscript.
Author Contributions
Conceived and designed the experiments: CM DG JM TV DC AK EES.
Performed the experiments: LEF AG MS MFC LM. Analyzed the data:
JMJD HZ CM DM DG BZ JM KS WZ LM DC AK EES. Contributed
reagents/materials/analysis tools: WZ. Wrote the paper: JMJD DM.
References
1. Hunter KW, Crawford NP (2008) The future of mouse QTL mapping to
diagnose disease in mice in the age of whole-genome association studies. Annu
Rev Genet 42: 131–141.
2. Bystrykh L, Weersing E, Dontje B, Sutton S, Pletcher MT, et al. (2005)
Uncovering regulatory pathways that affect hematopoietic stem cell function
using ‘genetical genomics’. Nat Genet 37: 225–232.
3. Chesler EJ, Lu L, Shou S, Qu Y, Gu J, et al. (2005) Complex trait analysis of
gene expression uncovers polygenic and pleiotropic networks that modulate
nervous system function. Nat Genet 37: 233–242.
4. Hubner N, Wallace CA, Zimdahl H, Petretto E, Schulz H, et al. (2005)
Integrated transcriptional profiling and linkage analysis for identification of
genes underlying disease. Nat Genet 37: 243–253.
5. Schadt EE, Lamb J, Yang X, Zhu J, Edwards S, et al. (2005) An integrative
genomics approach to infer causal associations between gene expression and
disease. Nat Genet 37: 710–717.
6. Schadt EE, Monks SA, Drake TA, Lusis AJ, Che N, et al. (2003) Genetics of
gene expression surveyed in maize, mouse and man. Nature 422: 297–302.
7. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, et al. (2003)
Seventh report of the Joint National Committee on Prevention, Detection,
Evaluation, andTreatmentof High Blood Pressure.Hypertension42:1206–1252.
8. Cornier MA, Dabelea D, Hernandez TL, Lindstrom RC, Steig AJ, et al. (2008)
The metabolic syndrome. Endocr Rev 29: 777–822.
9. Smith SC, Jr. (2007) Multiple risk factors for cardiovascular disease and diabetes
mellitus. Am J Med 120: S3–S11.
10. Sugiyama F, Churchill GA, Higgins DC, Johns C, Makaritsis KP, et al. (2001)
Concordance of murine quantitative trait loci for salt-induced hypertension with
rat and human loci. Genomics 71: 70–77.
11. Stoll M, Cowley AW, Jr., Tonellato PJ, Greene AS, Kaldunski ML, et al. (2001) A
genomic-systemsbiology map for cardiovascular function. Science 294: 1723–1726.
12. Wang X, Ishimori N, Korstanje R, Rollins J, Paigen B (2005) Identifying novel
genes foratherosclerosis through mouse-humancomparativegenetics.AmJHum
Genet 77: 1–15.
13. Wuschke S, Dahm S, Schmidt C, Joost HG, Al-Hasani H (2007) A meta-analysis
of quantitative trait loci associated with body weight and adiposity in mice.
Int J Obes (Lond) 31: 829–841.
14. Wright FA, O’Connor DT, Roberts E, Kutey G, Berry CC, et al. (1999)
Genome scan for blood pressure loci in mice. Hypertension 34: 625–630.
15. Sugiyama F, Churchill GA, Li R, Libby LJ, Carver T, et al. (2002) QTL
associated with blood pressure, heart rate, and heart weight in CBA/CaJ and
BALB/cJ mice. Physiol Genomics 10: 5–12.
16. DiPetrillo K, Tsaih SW, Sheehan S, Johns C, Kelmenson P, et al. (2004) Genetic
analysis of blood pressure in C3H/HeJ and SWR/J mice. Physiol Genomics 17:
215–220.
17. Cowley AW, Jr. (2006) The genetic dissection of essential hypertension. Nat Rev
Genet 7: 829–840.
18. Woo DD, Kurtz I (2003) Mapping blood pressure loci in (A/J x B6)F2 mice.
Physiol Genomics 15: 236–242.
19. Kruglyak L, Lander ES (1995) A nonparametric approach for mapping
quantitative trait loci. Genetics 139: 1421–1428.
20. Zhang S, Gershenfeld HK (2003) Genetic contributions to body weight in mice:
relationship of exploratory behavior to weight. Obes Res 11: 828–838.
21. Shao H, Burrage LC, Sinasac DS, Hill AE, Ernest SR, et al. (2008) Genetic
architecture of complex traits: large phenotypic effects and pervasive epistasis.
Proc Natl Acad Sci U S A 105: 19910–19914.
Networks and Metabolism
PLoS ONE | www.plosone.org 13 December 2010 | Volume 5 | Issue 12 | e1431922. Suzuki M, Carlson KM, Marchuk DA, Rockman HA (2002) Genetic modifier
loci affecting survival and cardiac function in murine dilated cardiomyopathy.
Circulation 105: 1824–1829.
23. Pagliarini DJ, Calvo SE, Chang B, Sheth SA, Vafai SB, et al. (2008) A
mitochondrial protein compendium elucidates complex I disease biology. Cell
134: 112–123.
24. Chen Y, Zhu J, Lum PY, Yang X, Pinto S, et al. (2008) Variations in DNA
elucidate molecular networks that cause disease. Nature 452: 429–435.
25. Emilsson V, Thorleifsson G, Zhang B, Leonardson AS, Zink F, et al. (2008)
Genetics of gene expression and its effect on disease. Nature 452: 423–428.
26. Gargalovic PS, Imura M, Zhang B, Gharavi NM, Clark MJ, et al. (2006)
Identification of inflammatory gene modules based on variations of human
endothelial cell responses to oxidized lipids. Proc Natl Acad Sci U S A 103:
12741–12746.
27. Ghazalpour A, Doss S, Zhang B, Wang S, Plaisier C, et al. (2006) Integrating
genetic and network analysis to characterize genes related to mouse weight.
PLoS Genet 2: e130.
28. Horvath S, Zhang B, Carlson M, Lu KV, Zhu S, et al. (2006) Analysis of
oncogenic signaling networks in glioblastoma identifies ASPM as a molecular
target. Proc Natl Acad Sci U S A 103: 17402–17407.
29. Schadt EE, Molony C, Chudin E, Hao K, Yang X, et al. (2008) Mapping the
genetic architecture of gene expression in human liver. PLoS Biol 6: e107.
30. Zhang B, Horvath S (2005) A general framework for weighted gene co-
expression network analysis. Stat Appl Genet Mol Biol 4: Article17.
31. Zhu J, Zhang B, Schadt EE (2008) A systems biology approach to drug
discovery. Adv Genet 60: 603–635.
32. Zhu J, Zhang B, Smith EN, Drees B, Brem RB, et al. (2008) Integrating large-
scale functional genomic data to dissect the complexity of yeast regulatory
networks. Nat Genet 40: 854–861.
33. Cervino AC, Li G, Edwards S, Zhu J, Laurie C, et al. (2005) Integrating QTL
and high-density SNP analyses in mice to identify Insig2 as a susceptibility gene
for plasma cholesterol levels. Genomics 86: 505–517.
34. Wang S, Yehya N, Schadt EE, Wang H, Drake TA, et al. (2006) Genetic and
genomic analysis of a fat mass trait with complex inheritance reveals marked sex
specificity. PLoS Genet 2: e15.
35. Zeggini E, Scott LJ, Saxena R, Voight BF, Marchini JL, et al. (2008) Meta-
analysis of genome-wide association data and large-scale replication identifies
additional susceptibility loci for type 2 diabetes. Nat Genet 40: 638–645.
36. Dina C, Meyre D, Gallina S, Durand E, Korner A, et al. (2007) Variation in
FTO contributes to childhood obesity and severe adult obesity. Nat Genet 39:
724–726.
37. Frayling TM, Timpson NJ, Weedon MN, Zeggini E, Freathy RM, et al. (2007)
A common variant in the FTO gene is associated with body mass index and
predisposes to childhood and adult obesity. Science 316: 889–894.
38. Scuteri A, Sanna S, Chen WM, Uda M, Albai G, et al. (2007) Genome-wide
association scan shows genetic variants in the FTO gene are associated with
obesity-related traits. PLoS Genet 3: e115.
39. Fischer J, Koch L, Emmerling C, Vierkotten J, Peters T, et al. (2009)
Inactivation of the Fto gene protects from obesity. Nature 458: 894–898.
40. Timpson NJ, Lindgren CM, Weedon MN, Randall J, Ouwehand WH, et al.
(2009) Adiposity-related heterogeneity in patterns of type 2 diabetes suscepti-
bility observed in genome-wide association data. Diabetes 58: 505–510.
41. Legry V, Cottel D, Ferrieres J, Arveiler D, Andrieux N, et al. (2009) Effect of an
FTO polymorphism on fat mass, obesity, and type 2 diabetes mellitus in the
French MONICA Study. Metabolism.
42. Zeggini E, Weedon MN, Lindgren CM, Frayling TM, Elliott KS, et al. (2007)
Replication of genome-wide association signals in UK samples reveals risk loci
for type 2 diabetes. Science 316: 1336–1341.
43. Feldmann HM, Golozoubova V, Cannon B, Nedergaard J (2009) UCP1
ablation induces obesity and abolishes diet-induced thermogenesis in mice
exempt from thermal stress by living at thermoneutrality. Cell Metab 9:
203–209.
44. Keller MP, Choi Y, Wang P, Davis DB, Rabaglia ME, et al. (2008) A gene
expression network model of type 2 diabetes links cell cycle regulation in islets
with diabetes susceptibility. Genome Res 18: 706–716.
45. Hamann J, Koning N, Pouwels W, Ulfman LH, van Eijk M, et al. (2007) EMR1,
the human homolog of F4/80, is an eosinophil-specific receptor. Eur J Immunol
37: 2797–2802.
46. Kwakkenbos MJ, Kop EN, Stacey M, Matmati M, Gordon S, et al. (2004) The
EGF-TM7 family: a postgenomic view. Immunogenetics 55: 655–666.
47. Heximer SP, Blumer KJ (2007) RGS proteins: Swiss army knives in seven-
transmembrane domain receptor signaling networks. Sci STKE 2007: pe2.
48. Heximer SP, Watson N, Linder ME, Blumer KJ, Hepler JR (1997) RGS2/G0S8
is a selective inhibitor of Gqalpha function. Proc Natl Acad Sci U S A 94:
14389–14393.
49. Nishizuka M, Honda K, Tsuchiya T, Nishihara T, Imagawa M (2001) RGS2
promotes adipocyte differentiation in the presence of ligand for peroxisome
proliferator-activated receptor gamma. J Biol Chem 276: 29625–29627.
50. Tang KM, Wang GR, Lu P, Karas RH, Aronovitz M, et al. (2003) Regulator of
G-protein signaling-2 mediates vascular smooth muscle relaxation and blood
pressure. Nat Med 9: 1506–1512.
51. Gross V, Tank J, Obst M, Plehm R, Blumer KJ, et al. (2005) Autonomic nervous
system and blood pressure regulation in RGS2-deficient mice. Am J Physiol
Regul Integr Comp Physiol 288: R1134–1142.
52. Heximer SP, Knutsen RH, Sun X, Kaltenbronn KM, Rhee MH, et al. (2003)
Hypertension and prolonged vasoconstrictor signaling in RGS2-deficient mice.
J Clin Invest 111: 445–452.
53. Riddle EL, Rana BK, Murthy KK, Rao F, Eskin E, et al. (2006) Polymorphisms
and haplotypes of the regulator of G protein signaling-2 gene in normotensives
and hypertensives. Hypertension 47: 415–420.
54. Yang J, Kamide K, Kokubo Y, Takiuchi S, Tanaka C, et al. (2005) Genetic
variations of regulator of G-protein signaling 2 in hypertensive patients and in
the general population. J Hypertens 23: 1497–1505.
55. Freson K, Stolarz K, Aerts R, Brand E, Brand-Herrmann SM, et al. (2007) -391
C to G substitution in the regulator of G-protein signalling-2 promoter increases
susceptibility to the metabolic syndrome in white European men: consistency
between molecular and epidemiological studies. J Hypertens 25: 117–125.
56. Sartori M, Ceolotto G, Dorigatti F, Mos L, Santonastaso M, et al. (2008) RGS2
C1114G polymorphism and body weight gain in hypertensive patients.
Metabolism 57: 421–427.
57. Petrash JM (2004) All in the family: aldose reductase and closely related aldo-
keto reductases. Cell Mol Life Sci 61: 737–749.
58. Hughes TR, Mao M, Jones AR, Burchard J, Marton MJ, et al. (2001) Expression
profiling using microarrays fabricated by an ink-jet oligonucleotide synthesizer.
Nat Biotechnol 19: 342–347.
59. Haley CS, Knott SA (1992) A simple regression method for mapping
quantitative trait loci in line crosses using flanking markers. Heredity 69:
315–324.
60. Broman KW, Wu H, Sen S, Churchill GA (2003) R/qtl: QTL mapping in
experimental crosses. Bioinformatics 19: 889–890.
61. Ravasz E, Somera AL, Mongru DA, Oltvai ZN, Barabasi AL (2002)
Hierarchical organization of modularity in metabolic networks. Science 297:
1551–1555.
62. Jiang C, Zeng ZB (1997) Mapping quantitative trait loci with dominant and
missing markers in various crosses from two inbred lines. Genetica 101: 47–58.
63. Sakamoto Y, Ishiguro M, Kitagawa G (1986) Akaike information criterion
statistics. Tokyo: KTK Scientific Publishers. 290 p.
64. Lin HH, Faunce DE, Stacey M, Terajewicz A, Nakamura T, et al. (2005) The
macrophage F4/80 receptor is required for the induction of antigen-specific
efferent regulatory T cells in peripheral tolerance. J Exp Med 201: 1615–1625.
65. Takeshita S, Moritani M, Kunika K, Inoue H, Itakura M (2006) Diabetic
modifier QTLs identified in F2 intercrosses between Akita and A/J mice.
Mamm Genome 17: 927–940.
66. Stylianou IM, Tsaih SW, DiPetrillo K, Ishimori N, Li R, et al. (2006) Complex
genetic architecture revealed by analysis of high-density lipoprotein cholesterol
in chromosome substitution strains and F2 crosses. Genetics 174: 999–1007.
Networks and Metabolism
PLoS ONE | www.plosone.org 14 December 2010 | Volume 5 | Issue 12 | e14319